Citi raised the firm’s price target on DexCom (DXCM) to $77 from $75 and keeps a Buy rating on the shares. Citi also opened an “upside 90-day catalyst watch” on DexCom. The firm sees the stock moving higher on the company’s 2026 guidance in January.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM:
- Teradyne upgraded, Circle Internet initiated: Wall Street’s top analyst calls
- DexCom upgraded to Overweight at Morgan Stanley with company turning corner
- DexCom upgraded to Overweight from Equal Weight at Morgan Stanley
- ServiceNow, Dexcom, Coinbase, Jumia, Keysight: Trending by Analysts
- OIG report looks positive for DexCom, says BofA